Sanofi-Translate Deal May Get Probed by FTC, Dealreporter Says

Sanofi’s planned acquisition of Translate Bio is likely to be probed by the Federal Trade Commission, Dealreporter said, citing two antitrust lawyers.

• Scrutiny is likely needed due to the existing partnerships and exclusive licensing agreements between the companies, the sources told Dealreporter
• The companies didn’t respond to requests for comments by Dealreporter
• SNY fell as much as 1.1%, TBIO -1.3% intraday
• NOTE: Aug. 3, Translate Bio Investors Get ‘Ideal Time to Sell,’ Says Leerink

To contact the reporter on this story:
Aoyon Ashraf in Toronto at aashraf7@bloomberg.net

To contact the editors responsible for this story:
Divya Balji at dbalji1@bloomberg.net

Philip ...